Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fidia's Hyalgan osteoarthritis injection U.S. launch to be backed by Sanofi, OrthoLogic direct reps.

This article was originally published in The Gray Sheet

Executive Summary

FIDIA'S HYALGAN TO BE BACKED BY 415-REP U.S. SALES FORCE in a market introduction of the hyaluronic acid-based knee joint injection product planned for July. Under an exclusive U.S. licensing deal announced June 25, Sanofi Pharmaceuticals will offer the product through 250 reps to rheumatologists, family practice physicians and others who treat osteoarthritis except for orthopedic surgeons. A separate co-promotion agreement between Sanofi and OrthoLogic will provide an additional 165 reps targeting orthopedic surgeons.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel